Payment overview · 2025
General Payments
$2,152.46
109 reported records · 25 companies
Healthcare provider profile · identity verified
Michael D Satchell, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, GA · NPI 1205822806
Verified facts
What the public records show
CMS Open Payments records show Michael D Satchell, MD received $2,152.46 in general payments during 2025 across 109 reported records.
Neurocrine BioSciences, Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Gemtesa, Ingrezza, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 541 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 1027 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 4053 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 1027 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 4053 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $379.64 | 17.6% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $253.12 | 11.8% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $195.22 | 9.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $168.01 | 7.8% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $156.82 | 7.3% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.37 | 6.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.36 | 5.9% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.23 | 5.1% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.79 | 4.5% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $75.84 | 3.5% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $66.57 | 3.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.87 | 3.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.92 | 2.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.58 | 2.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.37 | 2.2% | 3 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $21.92 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.13 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.69 | 0.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.14 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.35 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.01 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.89 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.32 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.67 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,152.46 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $379.64 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $195.22 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $156.82 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $141.37 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.06 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.43 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.95 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.62 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $95.79 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $92.45 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.62 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.39 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $75.84 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $71.39 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $66.57 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.87 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.74 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.74 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $48.37 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.69 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 62 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 4053 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 132 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 1027 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 170 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 141 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 340 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
170 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
541 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
87 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
1027 | 86 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
4053 | 177 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
62 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
1027 | 86 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
141 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
159 | 24 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
318 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
340 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
4053 | 177 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
132 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12052 | 456 |
| Amlodipine Besylate | Amlodipine Besylate | 8627 | 439 |
| Famotidine | Famotidine | 7532 | 355 |
| Gabapentin | Gabapentin | 7306 | 313 |
| Furosemide | Furosemide | 6522 | 321 |
| Potassium Chloride | Potassium Chloride | 6101 | 333 |
| Mirtazapine | Mirtazapine | 4495 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 4477 | 184 |
| Tamsulosin Hcl | Tamsulosin Hcl | 4060 | 208 |
| Eliquis | Apixaban | 4053 | 177 |
| Donepezil Hcl | Donepezil Hcl | 3983 | 134 |
| Metoprolol Tartrate | Metoprolol Tartrate | 3788 | 182 |
| Sertraline Hcl | Sertraline Hcl | 3696 | 141 |
| Lisinopril | Lisinopril | 3565 | 173 |
| Clopidogrel | Clopidogrel Bisulfate | 3526 | 144 |
| Trazodone Hcl | Trazodone Hcl | 3523 | 143 |
| Metformin Hcl | Metformin Hcl | 3450 | 194 |
| Omeprazole | Omeprazole | 3380 | 238 |
| Losartan Potassium | Losartan Potassium | 3281 | 225 |
| Quetiapine Fumarate | Quetiapine Fumarate | 3204 | 118 |
| Memantine Hcl | Memantine Hcl | 3162 | 112 |
| Levetiracetam | Levetiracetam | 2946 | 114 |
| Carvedilol | Carvedilol | 2941 | 148 |
| Divalproex Sodium | Divalproex Sodium | 2725 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 2549 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2512 | 243 |
| Hydralazine Hcl | Hydralazine Hcl | 2298 | 117 |
| Duloxetine Hcl | Duloxetine Hcl | 2092 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 2013 | 79 |
| Allopurinol | Allopurinol | 1839 | 91 |
| Buspirone Hcl | Buspirone Hcl | 1746 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 1410 | 110 |
| Tramadol Hcl | Tramadol Hcl | 1125 | 247 |
| Tizanidine Hcl | Tizanidine Hcl | 1110 | 113 |
| Xarelto | Rivaroxaban | 1101 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 1086 | 134 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1070 | 196 |
| Risperidone | Risperidone | 1055 | 40 |
| Jardiance | Empagliflozin | 1027 | 86 |
| Baclofen | Baclofen | 986 | 48 |
| Finasteride | Finasteride | 982 | 48 |
| Doxazosin Mesylate | Doxazosin Mesylate | 955 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 933 | 49 |
| Januvia | Sitagliptin Phosphate | 917 | 47 |
| Nifedipine Er | Nifedipine | 910 | 57 |
| Sucralfate | Sucralfate | 861 | 44 |
| Spironolactone | Spironolactone | 850 | 59 |
| Valsartan | Valsartan | 832 | 35 |
| Atenolol | Atenolol | 818 | 55 |
| Olanzapine | Olanzapine | 806 | 37 |
| Montelukast Sodium | Montelukast Sodium | 795 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 772 | 34 |
| Glipizide | Glipizide | 763 | 49 |
| Lorazepam | Lorazepam | 757 | 170 |
| Clonidine Hcl | Clonidine Hcl | 725 | 54 |
| Novolog Flexpen | Insulin Aspart | 694 | 118 |
| Tradjenta | Linagliptin | 676 | 24 |
| Prednisone | Prednisone | 606 | 91 |
| Topiramate | Topiramate | 604 | 15 |
| Meloxicam | Meloxicam | 563 | 61 |
| Myrbetriq | Mirabegron | 541 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 511 | 30 |
| Aripiprazole | Aripiprazole | 501 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 493 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 484 | 43 |
| Humalog Kwikpen U-100 | Insulin Lispro | 476 | 108 |
| Amiodarone Hcl | Amiodarone Hcl | 466 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 452 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 452 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 447 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 436 | 28 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 429 | 167 |
| Terazosin Hcl | Terazosin Hcl | 429 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 428 | 145 |
| Midodrine Hcl | Midodrine Hcl | 417 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 406 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 394 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 393 | 25 |
| Ziprasidone Hcl | Ziprasidone Hcl | 387 | suppressed |
| Chlorthalidone | Chlorthalidone | 386 | 19 |
| Ezetimibe | Ezetimibe | 386 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 383 | 72 |
| Pregabalin | Pregabalin | 383 | 72 |
| Propranolol Hcl | Propranolol Hcl | 382 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 375 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 346 | 56 |
| Lacosamide | Lacosamide | 340 | 28 |
| Rexulti | Brexpiprazole | 340 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 324 | 13 |
| Entresto | Sacubitril/Valsartan | 318 | 23 |
| Latanoprost | Latanoprost | 313 | 64 |
| Diclofenac Sodium | Diclofenac Sodium | 306 | 102 |
| Alprazolam | Alprazolam | 297 | 57 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 287 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 282 | 11 |
| Simvastatin | Simvastatin | 276 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 270 | 28 |
| Metformin Hcl Er | Metformin Hcl | 264 | 29 |
| Divalproex Sodium Er | Divalproex Sodium | 262 | suppressed |
| Glipizide Er | Glipizide | 255 | 13 |
| Primidone | Primidone | 250 | suppressed |
| Ondansetron Odt | Ondansetron | 246 | 113 |
| Ceftriaxone | Ceftriaxone Sodium | 244 | 163 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 240 | 47 |
| Clonazepam | Clonazepam | 238 | 34 |
| Calcium Acetate | Calcium Acetate | 235 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 235 | 12 |
| Glycopyrrolate | Glycopyrrolate | 231 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 229 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 224 | 12 |
| Memantine Hcl Er | Memantine Hcl | 223 | suppressed |
| Torsemide | Torsemide | 219 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 219 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 214 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 214 | suppressed |
| Lactulose | Lactulose | 210 | 40 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 199 | 45 |
| Haloperidol | Haloperidol | 197 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 197 | 41 |
| Bupropion Hcl | Bupropion Hcl | 195 | suppressed |
| Bumetanide | Bumetanide | 191 | 11 |
| Meclizine Hcl | Meclizine Hcl | 188 | 41 |
| Oxcarbazepine | Oxcarbazepine | 188 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 179 | 75 |
| Nystatin | Nystatin | 179 | 91 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 173 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 171 | 22 |
| Linzess | Linaclotide | 170 | 55 |
| Bupropion Xl | Bupropion Hcl | 167 | 26 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 167 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 167 | 39 |
| Alendronate Sodium | Alendronate Sodium | 165 | 31 |
| Mupirocin | Mupirocin | 163 | 62 |
| Trulicity | Dulaglutide | 159 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 157 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 155 | 92 |
| Sevelamer Carbonate | Sevelamer Carbonate | 154 | suppressed |
| Azithromycin | Azithromycin | 151 | 129 |
| Ondansetron Hcl | Ondansetron Hcl | 150 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 65 |
| Mounjaro | Tirzepatide | 141 | 23 |
| Enulose | Lactulose | 139 | 34 |
| Lamotrigine | Lamotrigine | 138 | suppressed |
| Phenytoin | Phenytoin | 135 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 134 | 105 |
| Tresiba Flextouch U-100 | Insulin Degludec | 133 | 24 |
| Gemtesa | Vibegron | 132 | suppressed |
| Ozempic | Semaglutide | 132 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 128 | 19 |
| Celecoxib | Celecoxib | 127 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 124 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 122 | 27 |
| Rivastigmine | Rivastigmine | 122 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 121 | 23 |
| Metolazone | Metolazone | 121 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 119 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 97 |
| Fluconazole | Fluconazole | 114 | 74 |
| Colchicine | Colchicine | 113 | 30 |
| Nystop | Nystatin | 111 | 52 |
| Doxepin Hcl | Doxepin Hcl | 110 | suppressed |
| Lubiprostone | Lubiprostone | 108 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 28 |
| Cephalexin | Cephalexin | 106 | 84 |
| Nuplazid | Pimavanserin Tartrate | 103 | suppressed |
| Carbamazepine Er | Carbamazepine | 101 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 98 | 54 |
| Austedo | Deutetrabenazine | 95 | suppressed |
| Carbamazepine | Carbamazepine | 95 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 95 | suppressed |
| Novolin R | Insulin Regular, Human | 95 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 93 | suppressed |
| Silodosin | Silodosin | 93 | suppressed |
| Levemir Flexpen | Insulin Detemir | 92 | 25 |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 92 | 11 |
| Anastrozole | Anastrozole | 91 | suppressed |
| Fenofibrate | Fenofibrate | 91 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 91 | 26 |
| Budesonide | Budesonide | 90 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 33 |
| Lokelma | Sodium Zirconium Cyclosilicate | 87 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 85 | suppressed |
| Levofloxacin | Levofloxacin | 85 | 67 |
| Temazepam | Temazepam | 85 | 17 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 84 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 83 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 83 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 83 | 44 |
| Scopolamine | Scopolamine | 82 | 11 |
| Diazepam | Diazepam | 80 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | suppressed |
| Ranolazine Er | Ranolazine | 80 | suppressed |
| Vraylar | Cariprazine Hcl | 79 | suppressed |
| Estradiol | Estradiol | 78 | suppressed |
| Glimepiride | Glimepiride | 76 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 75 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 74 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 72 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 69 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 69 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 68 | 27 |
| Farxiga | Dapagliflozin Propanediol | 68 | 12 |
| Methocarbamol | Methocarbamol | 67 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 66 | suppressed |
| Brilinta | Ticagrelor | 66 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 65 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 65 | suppressed |
| Novolog | Insulin Aspart | 65 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 62 | 61 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 62 | suppressed |
| Dexamethasone | Dexamethasone | 60 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 60 | 18 |
| Fenofibrate | Fenofibrate,micronized | 60 | suppressed |
| Ibuprofen | Ibuprofen | 60 | 26 |
| Ketoconazole | Ketoconazole | 60 | 28 |
| Phenobarbital | Phenobarbital | 60 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 59 | 42 |
| Verapamil Er | Verapamil Hcl | 59 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 57 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 57 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 56 | suppressed |
| Felodipine Er | Felodipine | 56 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 56 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 23 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 55 | 45 |
| Rybelsus | Semaglutide | 55 | 11 |
| Diltiazem 12hr Er | Diltiazem Hcl | 54 | suppressed |
| Fentanyl | Fentanyl | 54 | 12 |
| Xifaxan | Rifaximin | 54 | suppressed |
| Metronidazole | Metronidazole | 53 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 44 |
| Colesevelam Hcl | Colesevelam Hcl | 52 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 52 | suppressed |
| Movantik | Naloxegol Oxalate | 52 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 52 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 52 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 48 |
| Cilostazol | Cilostazol | 50 | suppressed |
| Humalog | Insulin Lispro | 50 | 21 |
| Sotalol | Sotalol Hcl | 50 | suppressed |
| Armour Thyroid | Thyroid,pork | 48 | suppressed |
| Methadone Hcl | Methadone Hcl | 48 | suppressed |
| Xtampza Er | Oxycodone Myristate | 48 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | suppressed |
| Cyclosporine | Cyclosporine | 47 | suppressed |
| Hydroxyurea | Hydroxyurea | 47 | suppressed |
| Minoxidil | Minoxidil | 47 | suppressed |
| Naproxen | Naproxen | 47 | 13 |
| Prazosin Hcl | Prazosin Hcl | 47 | suppressed |
| Calcitriol | Calcitriol | 46 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 44 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 44 | suppressed |
| Acetylcysteine | Acetylcysteine | 43 | suppressed |
| Folic Acid | Folic Acid | 43 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 42 | suppressed |
| Mesalamine Er | Mesalamine | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 41 | 15 |
| Tiotropium Bromide | Tiotropium Bromide | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 38 | 29 |
| Oxazepam | Oxazepam | 38 | suppressed |
| Clozapine | Clozapine | 37 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 37 | 25 |
| Indapamide | Indapamide | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | 14 |
| Exemestane | Exemestane | 35 | suppressed |
| Austedo Xr | Deutetrabenazine | 34 | suppressed |
| Creon | Lipase/Protease/Amylase | 34 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 13 |
| Mirabegron Er | Mirabegron | 33 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 33 | 12 |
| Clonidine | Clonidine | 32 | suppressed |
| Paliperidone Er | Paliperidone | 32 | suppressed |
| Leflunomide | Leflunomide | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Erythromycin | Erythromycin Base | 29 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Sotalol Af | Sotalol Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Etodolac | Etodolac | 28 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 28 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 28 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 26 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 22 | 11 |
| Lidocaine | Lidocaine | 22 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | 16 |
| Nitroglycerin | Nitroglycerin | 21 | 16 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 21 | 20 |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 19 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 18 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 18 | 12 |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 18 | 17 |
| Ursodiol | Ursodiol | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Digoxin | Digoxin | 17 | suppressed |
| Glucagen | Glucagon | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 16 |
| Pentasa | Mesalamine | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 16 | 12 |
| Nadolol | Nadolol | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Tobramycin | Tobramycin | 16 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Alprazolam Odt | Alprazolam | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Nifedipine | Nifedipine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Roflumilast | Roflumilast | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brinzolamide | Brinzolamide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,152.46 · 109 records | Neurocrine BioSciences, Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GEMTESA, IBSRELA, INGREZZA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PURAPLY WOUND MATRIX, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error